# Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure

## TL;DR

This paper discusses a case where baricitinib, a promising treatment for alopecia areata, failed to maintain results over time.

## Contribution

The paper presents a rare case of relapse in alopecia areata despite ongoing baricitinib treatment.

## Key findings

- A 30-year-old male with severe alopecia areata initially responded well to baricitinib.
- The patient later experienced a relapse despite continued treatment with baricitinib.

## Abstract

Alopecia areata (AA) has long been considered a challenging clinical condition, with dermatologists traditionally employing corticosteroids and immunosuppressants in search of effective solutions. The introduction of Janus kinase inhibitors (JAKi), specifically the Food and Drug Administration (FDA) approval of baricitinib, marked a significant breakthrough in the treatment of AA. Clinical trials have shown promising results with baricitinib, and reports of relapse after initial success are scarce. We present a unique case of a 30-year-old male with severe patch-type AA who initially responded well to baricitinib treatment but later experienced a relapse despite continued treatment.